Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics

Nordic Journal of Psychiatry

Volumn 65, Issue 5, 2011, Pages 345-352

  Krane Gartiser, Karoline ^a   Breum, Leif ^a   Glümrr, Charlotte ^a   Linneberg, Allan ^a   Madsen, Maiken ^a   Køster, Anne ^a   Jepsen, Peter W ^a   Fink Jensen, Anders ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antipsychotic drugs; IDF; Metabolic syndrome; Prevalence

Indexed keywords

CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; OUTPATIENT; POLYPHARMACY; PREVALENCE; RISK; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DENMARK; DIABETES MELLITUS; FEMALE; HUMANS; INCIDENCE; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OUTPATIENTS; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA; TRIGLYCERIDES;

EID: 80053036237     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2011.565799     Document Type: Article

References (30)

1. Alberti, KG, Zimmet P, Shaw J. The metabolic syndrome - A new worldwide definition. Lancet 2005;366:1059-62. (Pubitemid 41338752)
2. Executive summary of the third report of the national education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
3. McEvoy J P, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 2005;80:19-32. (Pubitemid 41587460)
4. Holt R, Abdelrahman T, Hirsch M, Dhesi Z, George T, Blincoe T, et al. The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. J Psychopharmacol 2010;24:867-73.
5. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry 2009;24:412-24.
6. Van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-45.
7. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 2007;64:1123-31.
8. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet 2009;374:620-27.
9. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia - A randomized doubleblind controlled, short-term prospective study. Schizophrenia Res 2008;101:266-72.
10. Stahl SM, Mignon L, Meyer JM. Which comes first: Atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119:171-9.
11. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naïve patients with first-episode psychosis. J Clin Psychiatry 2009;70:997-1000.
12. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophr Res 2008;104:1-12.
13. Newcomer J W. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry 2007;68:20-7.
14. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010;17:460-6.
15. Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: A register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder and schizophrenia. J Clin Psychiatry 2007;68:899-907. (Pubitemid 47015490)
16. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders 2008;10:788-97.
17. Suvisaari JM, Saarni SI, Perälä J, Suvisaari JV, Härkänen T, Lönnqvist J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007;68:1045-55. (Pubitemid 47340325)
18. John A P, Koloth R, Dragovic M, Lim SC. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009;190:176-9.
19. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. International Clin Psychopharmacology 2006;21:93-8. (Pubitemid 43740316)
20. Birkenaes AB, Søgaard AJ, Engh JA, Jonsdottir H, Ringen PA, Vaskinn A, et al. Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population. J Clin Psychiatry 2006;67:425-33.
21. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-579. (Pubitemid 36618288)
22. Larsen JT, Fagerquist M, Holdrup M, Christensen B, Sigalin C, Nilsson PM. Metabolic syndrome and psychiatrists'choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden. Nordic J Psych 2010;65:40-6.
23. Thyssen J P, Linneberg A, Menné T, Nielsen NH, Johansen JD. The prevalence and morbidity of sensitization to fragrance mix I in the general population. Br J Dermatol 2009;161:95-101.
24. Schorr SG, Slooff CJ, Bruggeman R, Taxis K. Prevalence of metabolic syndrome in patients with psychotic disorders in the Netherlands. J Clin Psychopharmacol 2009;29:399-402.
25. De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Res 2006;83:87-93.
26. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in firstepisode patients with schizophrenia: A retrospective chart review. Schizophrenia Res 2008;101:295-303.
27. Meyer JM, Davis VG, Goff DC, McEvoy J P, Nasrallah HA, Davis SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: Prospective data from phase 1. Schizophrenia Res 2008;101:273-86.
28. JBS 2: Joint British Societies'guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:v1-v52.
29. Nasrallah HA, Newcomer J W. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24:S7-14. (Pubitemid 39265949)
30. Madsbad S, Astrup AV. Obesity, the metabolic syndrome and cardiovascular disease. Ugeskrift for lœger 2004;166:1561-4. (Pubitemid 38525324)